Dry and Wet Age-Related Macular Degeneration | Disease Landscape & Forecast | G7 | 2024
Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula. We expect the historical mainstays of wet AMD treatment—off-label Avastin, Lucentis, and Eylea—to lose patient share to the newer entrants on the market (i.e., Roche / Chugai’s Vabysmo and Regeneron / Bayer’s Eylea HD) owing to their advantageous dosing regimen. Competition will increase in the wet AMD market with the launch of emerging therapies, including aflibercept biosimilars starting in 2024 in the United States, three gene therapies (i.e., Regenxbio / AbbVie’s ABBV-RGX-314, Adverum’s ixo-vec, and 4DMT’s 4D-150), and three TKIs (i.e., EyePoint Pharmaceuticals’ Duravyu, Ocular Therapeutix’s Axpaxli, and Clearside Biomedical’s CLS-AX), leading to market fragmentation. By contrast, the management of geographic atrophy is limited to Apellis’s Syfovre and Astellas’s Izervay in the United States. We expect the launch of J&J Innovative Medicines’ JNJ-1887 in the United States and AstraZeneca’s danicopan in the United States and Japan by the end of our forecast.
Questions answered
- How will the wet AMD treatment algorithm change as new products such as Vabysmo and Eylea HD gain traction? To what extent will they capitalize on the need for therapies with longer dosing intervals?
- How will biosimilars of Eylea impact market dynamics?
- How receptive are retinal specialists to novel gene therapy approaches and to emerging therapies for wet AMD and GA?
- What are U.S. retinal specialists’ first impressions of novel GA treatments?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
